Cytokinetics Inc.

CYTK Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CYTK Income Statement
CYTK Balance Sheet
CYTK Cash Flow
Congress Trading

Recent trades of CYTK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CYTK Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CYTK Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CYTK Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CYTK's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cardiac sarcomere inhibitors Aug. 20, 2024
  • Patent Title: Methods for treating heart failure by administering cardiac sarcomere activators May. 21, 2024
  • Patent Title: Bicyclic 1,4-diazepanones and therapeutic uses thereof May. 14, 2024
  • Patent Title: Cardiac sarcomere inhibitors Apr. 23, 2024
  • Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Apr. 16, 2024
  • Patent Title: Cardiac sarcomere inhibitors Apr. 09, 2024
  • Patent Title: Process for preparing aficamten Mar. 19, 2024
  • Patent Title: Cardiac sarcomere inhibitors Mar. 05, 2024
  • Patent Title: Heterocyclic compounds and their uses Jan. 30, 2024
  • Patent Title: Tetrahydroisoquinoline derivatives Oct. 25, 2022
  • Patent Title: Cardiac sarcomere inhibitors Oct. 18, 2022
  • Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Oct. 18, 2022
  • Patent Title: Salts and crystal forms of omecamtiv mecarbil Oct. 11, 2022
  • Patent Title: Cardiac sarcomere inhibitors Aug. 16, 2022
  • Patent Title: Heterocyclic compounds and their uses Jul. 12, 2022
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Jun. 28, 2022
  • Patent Title: Bisamide sarcomere activating compounds and uses thereof Apr. 12, 2022
  • Patent Title: Process for the preparation of an amino-pyrimidine and intermediates thereof Oct. 12, 2021
  • Patent Title: Compounds, compositions and methods Apr. 13, 2021
  • Patent Title: Cardiac sarcomere inhibitors Nov. 17, 2020
  • Patent Title: Methods for preparing substituted imidazo[4,5-b]pyrazines Sep. 08, 2020
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Sep. 08, 2020
  • Patent Title: Compounds, compositions and methods Aug. 20, 2019
  • Patent Title: Combination als therapy Apr. 30, 2019
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Apr. 30, 2019
  • Patent Title: Substituted pyridazines as skeletal muscle modulators Sep. 18, 2018
  • Patent Title: Compounds, compositions and methods Jul. 31, 2018
  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Jun. 12, 2018
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Aug. 15, 2017
  • Patent Title: Substituted pyridazines as skeletal muscle modulators Mar. 28, 2017
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Mar. 08, 2016
  • Patent Title: Compounds, compositions and methods Oct. 06, 2015
  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Sep. 15, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Apr. 28, 2015
  • Patent Title: Amino-pyridazine skeletal muscle modulators Mar. 03, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Feb. 24, 2015
  • Patent Title: Certain chemical entities, compositions, and methods Nov. 25, 2014
  • Patent Title: Ureas and their use in the treatment of heart failure Oct. 28, 2014
  • Patent Title: Certain chemical entities, compositions and methods Oct. 28, 2014
  • Patent Title: Imidazole-benzamide anti-cancer agents Jul. 08, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Jun. 24, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Jun. 24, 2014
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use May. 06, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Apr. 01, 2014
  • Patent Title: Methods and compositions utilizing quinazolinones Feb. 25, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Feb. 18, 2014
  • Patent Title: Compounds, compositions and methods Jan. 21, 2014
  • Patent Title: Heterocyclic sulfonamides Dec. 10, 2013
  • Patent Title: Ureas and their use in the treatment of heart failure Aug. 20, 2013
  • Patent Title: Methods and compositions utilizing quinazolinones Jun. 25, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CYTK in WallStreetBets Daily Discussion

CYTK News

Recent insights relating to CYTK

CNBC Recommendations

Recent picks made for CYTK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYTK

CYTK Top Shareholders
Shareholder
Shares Held
CYTK Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CYTK Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CYTK Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top